In a subsequent step, drug characteristics are presented only for those who reported illicit drug use (n = 385).
Mass spectrometry imaging is standard in Big-Pharna, where drug characteristics data requested by the FDA are determined.
In order to improve on both the efficacy and safety profiles ofnovel medicines, a detailed understanding of both drug characteristics, andmechanism of drug action is needed.
In order to overcome such limitations, in this study we have decided to establish a methodological approach focusing primarily on drug characteristics.
These drug characteristics are needed for both efficacy-, and safety improvements, and also requested by regulatory authorities like; FDA/EMA/MHLW.
Their application leads to a better understanding of drug characteristics early on, thereby facilitating the design of dose-finding studies in the target patient population and saving resources.
Differences in triptan's therapeutic effects among individuals and drug characteristics, as well as lack of evidence for selecting a suitable drug for each patient are problems to be resolved.
However, differences in their therapeutic effects among individuals and drug characteristics, as well as lack of evidence for selecting a suitable drug for each patient are problems to be resolved[3].
Drug absorption from the gastrointestinal (GI) tract is a highly complex process dependent upon numerous factors including the physicochemical properties of the drug, characteristics of the formulation and interplay with the underlying physiological properties of the GI tract.
A detailed study of the effect of hydrogel and drug characteristics and physiological conditions is performed to gain a fundamental insight into the drug release behavior, which may be useful in the design of pH-responsive drug carriers.
Results show that the sensitivity of the PEC for the two drugs to the measures investigated reflects the distinct drug characteristics, suggesting that in order to ensure the successful reduction of a broad range of substances, a spectrum of measures targeting the entire lifecycle of a pharmaceutical should be implemented.
